Takeda Pharmaceutical Co Ltd 4502
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 4502 is a good fit for your portfolio.
News
-
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
-
Takeda Pharmaceutical's Third-Quarter Net Profit Dropped on Lower Margins — Update
-
Takeda Pharmaceutical's Third-Quarter Net Profit Dropped on Lower Margins
-
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda
-
Takeda Gets Chinese Regulatory Approval for Livtencity
-
Takeda Gets FDA Approval For Blood-Clotting Disorder Treatment
-
Takeda says FDA approves its treatment for colorectal cancer
-
Takeda Says FDA Approves Treatment for Colorectal Cancer
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 15.42
- Price/Sales
- 1.54
- Dividend Yield (Trailing)
- 4.62%
- Dividend Yield (Forward)
- 4.62%
- Total Yield
- 4.66%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 49,095
- Website
- https://www.takeda.com
Competitors
Valuation
|
Metric
|
4502
|
4568
|
4519
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.42 | 41.92 | 27.16 |
Price/Book Value | 0.95 | 5.72 | 5.21 |
Price/Sales | 1.54 | 6.03 | 8.18 |
Price/Cash Flow | 8.01 | 32.72 | 25.50 |
Price/Earnings
4502
4568
4519
Financial Strength
|
Metric
|
4502
|
4568
|
4519
|
|---|---|---|---|
Quick Ratio | 0.46 | 2.74 | 4.21 |
Current Ratio | 1.06 | 3.49 | 5.53 |
Interest Coverage | 1.93 | 11.76 | — |
Quick Ratio
4502
4568
4519
Profitability
|
Metric
|
4502
|
4568
|
4519
|
|---|---|---|---|
Return on Assets (Normalized) | 2.86% | 7.33% | 17.64% |
Return on Equity (Normalized) | 6.13% | 13.01% | 21.05% |
Return on Invested Capital (Normalized) | 4.78% | 11.32% | 20.98% |
Return on Assets
4502
4568
4519
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Hqpvwwxmjm | Dryz | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Cpgbrfmk | Frgrbf | $70.8 Bil | |
HLN
| Haleon PLC ADR | Mnszqwqm | Fgg | $38.2 Bil | |
VTRS
| Viatris Inc | Dtpyznmq | Trqh | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Vhtvgql | Wjk | $12.5 Bil | |
CTLT
| Catalent Inc | Gzqtcbgy | Ghscq | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Zltwrwrw | Sfkz | $4.3 Bil | |
CURLF
| Curaleaf Holdings Inc | Dddcpqgt | Hpq | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Qrqjpckdv | Kcsbs | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Yzxvcyxv | Dfqwb | $2.9 Bil |